|Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1|
X Wu, ZY Yang, Y Li, CM Hogerkorp, WR Schief, MS Seaman, T Zhou, ...
Science 329 (5993), 856-861, 2010
|Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies|
JR Mascola, G Stiegler, TC VanCott, H Katinger, CB Carpenter, ...
Nature medicine 6 (2), 207-210, 2000
|Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies|
M Li, F Gao, JR Mascola, L Stamatatos, VR Polonis, M Koutsoukos, ...
Journal of virology 79 (16), 10108-10125, 2005
|Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01|
T Zhou, I Georgiev, X Wu, ZY Yang, K Dai, A Finzi, Y Do Kwon, JF Scheid, ...
Science 329 (5993), 811-817, 2010
|An mRNA vaccine against SARS-CoV-2—preliminary report|
LA Jackson, EJ Anderson, NG Rouphael, PC Roberts, M Makhene, ...
New England Journal of Medicine, 2020
|Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine|
LR Baden, HM El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, ...
New England Journal of Medicine 384 (5), 403-416, 2021
|Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies|
JR Mascola, MG Lewis, G Stiegler, D Harris, TC VanCott, D Hayes, ...
Journal of virology 73 (5), 4009-4018, 1999
|Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals|
JF Scheid, H Mouquet, N Feldhahn, MS Seaman, K Velinzon, J Pietzsch, ...
Nature 458 (7238), 636-640, 2009
|Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus|
HX Liao, R Lynch, T Zhou, F Gao, SM Alam, SD Boyd, AZ Fire, KM Roskin, ...
Nature 496 (7446), 469-476, 2013
|Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9|
JS McLellan, M Pancera, C Carrico, J Gorman, JP Julien, R Khayat, ...
Nature 480 (7377), 336-343, 2011
|Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing|
X Wu, T Zhou, J Zhu, B Zhang, I Georgiev, C Wang, X Chen, NS Longo, ...
Science 333 (6049), 1593-1602, 2011
|Human skin Langerhans cells are targets of dengue virus infection|
SJL Wu, G Grouard-Vogel, W Sun, JR Mascola, E Brachtel, R Putvatana, ...
Nature medicine 6 (7), 816-820, 2000
|Broad and potent neutralization of HIV-1 by a gp41-specific human antibody|
J Huang, G Ofek, L Laub, MK Louder, NA Doria-Rose, NS Longo, ...
Nature 491 (7424), 406-412, 2012
|Structure and immune recognition of trimeric pre-fusion HIV-1 Env|
M Pancera, T Zhou, A Druz, IS Georgiev, C Soto, J Gorman, J Huang, ...
Nature 514 (7523), 455-461, 2014
|Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies|
NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ...
Nature 509 (7498), 55-62, 2014
|Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies|
MS Seaman, H Janes, N Hawkins, LE Grandpre, C Devoy, A Giri, ...
Journal of virology 84 (3), 1439-1452, 2010
|Gene transfer in humans using a conditionally replicating lentiviral vector|
BL Levine, LM Humeau, J Boyer, RR MacGregor, T Rebello, X Lu, ...
Proceedings of the National Academy of Sciences 103 (46), 17372-17377, 2006
|The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression|
NL Michael, G Chang, LG Loum, JR Mascola, D Dondero, DL Birx, ...
Nature medicine 3 (3), 338-340, 1997
|Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope|
G Ofek, M Tang, A Sambor, H Katinger, JR Mascola, R Wyatt, PD Kwong
Journal of virology 78 (19), 10724-10737, 2004
|Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine|
SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ...
New England Journal of Medicine 369 (22), 2083-2092, 2013